Get the Stockscreener App
2.22
0.45%
0.01
Grace Therapeutics Inc stock is traded at $2.22, with a volume of 210.03K.
It is up +0.45% in the last 24 hours and up +2.78% over the past month.
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage. Other products are GTx-102 Ataxia-Telangiectasia, GTx-101 Postherpetic Neuralgia, and GTx-201.
See More
Previous Close:
$2.21
Open:
$2.22
24h Volume:
210.03K
Relative Volume:
0.28
Market Cap:
$34.35M
Revenue:
-
Net Income/Loss:
$-5.98M
P/E Ratio:
-6.1615
EPS:
-0.3603
Net Cash Flow:
$-9.83M
1W Performance:
-4.72%
1M Performance:
+2.78%
6M Performance:
-33.53%
1Y Performance:
-23.18%
1-Day Range:
$2.16
$2.265
1-Week Range:
$2.13
$2.39
52-Week Range:
$1.79
$5.18
Grace Therapeutics Inc Stock (GRCE) Company Profile
Name
Grace Therapeutics Inc
Sector
Industry
Phone
609-322-1602
Address
103 CARNEGIE CENTER, PRINCETON
Compare GRCE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRCE
Grace Therapeutics Inc
|
2.22 | 34.20M | 0 | -5.98M | -9.83M | -0.3603 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Grace Therapeutics Inc Stock (GRCE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-02-25 | Initiated | TD Cowen | Buy |
| Sep-01-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-06-20 | Upgrade | B. Riley FBR | Neutral → Buy |
| Jan-13-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Aug-29-19 | Initiated | B. Riley FBR | Buy |
| Jul-18-19 | Initiated | Oppenheimer | Outperform |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
View All
Grace Therapeutics Inc Stock (GRCE) Latest News
GRCE Q1 2026 Earnings: EPS Beats Estimates by Wide Margin Amid No Reported RevenueProfit Margin Analysis - newsline.com
GRCE Stock On Retail Watchlist: High-Stakes FDA Decision On Brain Bleed Drug Nears - Stocktwits
GRCE Should I Buy - Intellectia AI
GRACE THERAPEUTICS INC (GRCE) Stock Chart - ChartMill
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Grace Therapeutics, Inc. (GRCE) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - Lelezard
Grace Therapeutics, Inc. (GRCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
GRCE Stock On Track For Worst Week In 5.5 Years — What’s Driving The Selloff? - Stocktwits
Grace Therapeutics, Inc. (GRCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-06-07 | Grace Therapeutics, Inc. (GRCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:GRCE | Press Release - Stockhouse
We're Keeping An Eye On Grace Therapeutics' (NASDAQ:GRCE) Cash Burn Rate - Sahm
Grace Therapeutics VP of Clinical Operations Departs Role - TipRanks
Grace Therapeutics (NASDAQ: GRCE) VP departs, enters 12‑month consulting agreement - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Is Investigating Grace Therapeutics, Inc. (GRCE) And Encourages Investors to Connect - ACCESS Newswire
2026-06-05 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Grace Therapeutics, Inc. (GRCE) And Encourages Investors to Connect | NDAQ:GRCE | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Encourages Grace Therapeutics - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Grace Therapeutics, Inc. (GRCE) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
GRCE INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Grace Therapeutics, Inc. - mykxlg.com
GRCE INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Grace Therapeutics, Inc. - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
2026-06-03 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Grace Therapeutics, Inc. (GRCE) and Encourages Investors to Learn More About the Investigation | NDAQ:GRCE | Press Release - Stockhouse
GRCE Technical Analysis | Trend, Signals & Chart Patterns | GRACE THERAPEUTICS INC (NASDAQ:GRCE) - ChartMill
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Grace Therapeutics, Inc. (GRCE) And Encourages Stockholders to Reach Out - ACCESS Newswire
Grace Therapeutics: A Manufacturing Setback Priced As A Death Sentence (NASDAQ:GRCE) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Is Investigating Grace Therape - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Grace Therapeutics, Inc. (GRCE) And Encourages Stockholders to Connect - ACCESS Newswire
2026-05-31 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Grace Therapeutics, Inc. (GRCE) And Encourages Stockholders to Connect | NDAQ:GRCE | Press Release - Stockhouse
Grace Therapeutics (GRCE) Jumps 5.76%: Testing Resistance at $2.7 After Support HoldPullback Trade - newsline.com
Grace Therapeutics, Inc. (GRCE) Investigation: Bronstein, Gewirtz - The National Law Review
GRCE Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Stock RallyLong-Term Guidance - The Legal Advocate
GRCE Q1 2026 Earnings: EPS Surprises to the Upside Despite No RevenueFinal Results - The Legal Advocate
GRCE Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineGuidance Accuracy Score - Newser
Grace Therapeutics Inc. (GRCE) Q1 2026 Earnings: Narrowed Loss Beats Expectations Despite Stock DipRevenue Guidance Update - The Legal Advocate
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc.GRCE - PR Newswire
Pomerantz LLP Investigates Claims for Grace Therapeutics Investors - Intellectia AI
Grace Therapeutics (GRCE) Gains +1.40% — Support Holds at $2.07 2026-05-20Intraday Profile - Newser
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc.GRCE - FinancialContent
Why Is Grace Therapeutics, Inc. (GRCE) Stock Down Today? - Meyka
Grace Therapeutics (GRCE) Q1 2026 Earnings Beat: Revenue $N/A, EPS $-0.14Mature Phase - Newser
Grace Therapeutics (GRCE) price target decreased by 47.83% to 6.12 - MSN
Grace Therapeutics (GRCE) Q1 2026 Earnings: $-0.14 EPS Surges Past $-0.29 EstimatesSocial Trade Signals - newser.com
ADAR1 reports 1.72M shares in Grace Therapeutics (GRCE) - Stock Titan
Grace Therapeutics faces investigation after FDA rejects drug application, stock drops 45%. - Pluang
GRCE Stock Plunges 45% After FDA Rejects Brain Injury Drug — Company Says Concerns Are Fixable - MSN
Grace Therapeutics (GRCE) Down -1.78% — How Low Could It Go? 2026-05-14Hedge Fund Inspired Picks - Newser
Number of shareholders of Grace Therapeutics, Inc. – NASDAQ:GRCE - TradingView
Number of shareholders of Grace Therapeutics, Inc. – FWB:L8S - TradingView
Largest borrow rate increases among liquid names - TipRanks
Grace Therapeutics, Inc. (GRCE) Eps Diluted (TTM) - Zacks Investment Research
Grace Therapeutics Inc Stock (GRCE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):